[go: up one dir, main page]

MA26985A1 - Derives d'amides de thiazolyl-,oxazolyl-pyrrolyl-et imidazolyl-acides utiles comme inhibiteurs d'isozymes pde4 - Google Patents

Derives d'amides de thiazolyl-,oxazolyl-pyrrolyl-et imidazolyl-acides utiles comme inhibiteurs d'isozymes pde4

Info

Publication number
MA26985A1
MA26985A1 MA27243A MA27243A MA26985A1 MA 26985 A1 MA26985 A1 MA 26985A1 MA 27243 A MA27243 A MA 27243A MA 27243 A MA27243 A MA 27243A MA 26985 A1 MA26985 A1 MA 26985A1
Authority
MA
Morocco
Prior art keywords
group
inhibitors
alkyl
represent
groups
Prior art date
Application number
MA27243A
Other languages
English (en)
Inventor
Anthony Marfat
Michael William Mckechney
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26985A1 publication Critical patent/MA26985A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 31 Janvier 2001 60/265,486 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés d'amides de thiazolyl-, oxazolyl-, pyrrolyl- et imidazolyl-acides utiles comme inhibiteurs d'isozymes PDE4 Composés utiles comme inhibiteurs de PDE4 dans le traitement de maladies, régulées par l'activation et la dégranulation des cellules éosinophiles, notamment l'asthme, la bronchite chronique, et une maladie pulmonaire obstructive chronique, de formule (I), dans laquelle j est égal à 0 ou 1 ; k est égal à 0 ou 1 ; m est égal à 0, 1, 2 ou 3 ; n est égal à 1 ou 2 ; W1 représente un groupe -O- ; ou -S(=O)t-, dans lequel t est égal à 0, 1 ou 2 ; ou -N(R3)- ; W2 représente un groupe -O-CRARB-ou est absent ; Y représente un groupe =C(R1a) ou - [N(flèche) (O) k] -, dans lequel k est égal à 0 ou 1 ; RA et RB représentent des groupes -H ; -F ; -CF3 ; -(alkyle en C1 à C4) ; - (cycloalkyle en C3 à C7), phényle ; ou benzyle substitué avec 0 à 3 substituants R10 ; ou bien RA et RB sont pris conjointement, mais seulement dans le cas oé m est égal à 1, pour former un groupement spiro ; Rc et RD répondent aux définitions de RA et RB, sauf qu'un d'entre eux doit représenter -H ; R1 et R2 représentent des groupes -H ; -F ; -Cl ; -CN ; -NO2 ; -(alkyle en C1 à C4) ; -(alcynyle en C2 à C4) ; - (fluoralkyle en C1 à C3) ; -OR16 ; ou -C (=O) NR22aR22b ; R3 représente -H ; un groupe -(alkyle en C1 à C3) ; phényle ; benzyle ; ou -OR16; R4, R5 et R6, en plus d'autres définitions, peuvent être pris conjointement pour former la formule (II) ; G1 représente un système de noyau carboné saturé ou insaturé ; dans lequel, facultativement, un atome de carbone peut être remplacé par un hétéroatome choisi entre N, O et S ; G2 représente un système de noyau carboné saturé ou insaturé ; dans lequel un atome de carbone peut être remplacé par un hétéroatome choisi entre N, O et S ; et E est choisi parmi les groupes de formule (III).
MA27243A 2001-01-31 2003-07-21 Derives d'amides de thiazolyl-,oxazolyl-pyrrolyl-et imidazolyl-acides utiles comme inhibiteurs d'isozymes pde4 MA26985A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26548601P 2001-01-31 2001-01-31

Publications (1)

Publication Number Publication Date
MA26985A1 true MA26985A1 (fr) 2004-12-20

Family

ID=23010641

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27243A MA26985A1 (fr) 2001-01-31 2003-07-21 Derives d'amides de thiazolyl-,oxazolyl-pyrrolyl-et imidazolyl-acides utiles comme inhibiteurs d'isozymes pde4

Country Status (24)

Country Link
US (3) US6559168B2 (fr)
EP (1) EP1355907A1 (fr)
JP (1) JP2004518691A (fr)
KR (1) KR20030072614A (fr)
CN (1) CN1489588A (fr)
BG (1) BG108039A (fr)
BR (1) BR0116850A (fr)
CA (1) CA2436551A1 (fr)
CR (1) CR7038A (fr)
CZ (1) CZ20031903A3 (fr)
EA (1) EA200300622A1 (fr)
EC (1) ECSP034683A (fr)
EE (1) EE200300362A (fr)
HU (1) HUP0401305A2 (fr)
IL (1) IL156412A0 (fr)
IS (1) IS6844A (fr)
MA (1) MA26985A1 (fr)
MX (1) MXPA03006886A (fr)
NO (1) NO20033398L (fr)
OA (1) OA12542A (fr)
PL (1) PL365443A1 (fr)
TN (1) TNSN03050A1 (fr)
WO (1) WO2002060898A1 (fr)
ZA (1) ZA200305769B (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1371650A4 (fr) * 2001-03-23 2005-05-04 Nippon Chemiphar Co Activateur de recepteur active par les proliferateurs du peroxysome
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
CN1520313A (zh) 2001-05-23 2004-08-11 ������ҩ��ʽ���� 一种加速骨折愈合的组合物
EP1389467B1 (fr) 2001-05-23 2013-07-03 Mitsubishi Tanabe Pharma Corporation Composition thérapeutique permettant le traitement régénératif des maladies de cartilage
JPWO2003020313A1 (ja) * 2001-09-04 2004-12-16 小野薬品工業株式会社 スフィンゴシン−１−リン酸受容体調節剤からなる呼吸器疾患治療剤
ATE521599T1 (de) * 2001-12-21 2011-09-15 X Ceptor Therapeutics Inc Heterocyclische modulatoren von nukleären rezeptoren
WO2003055482A1 (fr) * 2001-12-21 2003-07-10 Novo Nordisk A/S Derives amide utiles en tant qu'activateurs de la glucokinase
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
EP1470826B1 (fr) * 2002-02-01 2009-01-28 AnGes MG, Inc. Compositions pharmaceutiques contenant un leurre pour le traitement d'aneurysmes
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
PL215132B1 (pl) * 2002-06-27 2013-10-31 Novo Nordisk As Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
GB0217196D0 (en) * 2002-07-25 2002-09-04 Glaxo Group Ltd Medicament dispenser
FI114917B (fi) * 2002-08-29 2005-01-31 Hormos Nutraceutical Oy Ltd Lignaanikomplekseja
EP1567136A1 (fr) * 2002-11-27 2005-08-31 ALTANA Pharma AG Inhibiteurs de pde4 et pde3/4 que l'on utilise dans le traitement de la cachexie
US7148248B2 (en) * 2002-11-29 2006-12-12 Masako Nozaki Method of treating or inhibiting the development of brain inflammation and sepsis
EP1424101A3 (fr) * 2002-11-29 2004-08-18 NOZAKI, Masako Utilisation d'un antagoniste du leucotriène c4/d4 pour la préparation d'un médicament pour le traitement ou la prévention d'une inflammation ou septicémie du cerveau
WO2004060346A2 (fr) 2002-12-30 2004-07-22 Angiotech International Ag Liberation de medicaments a partir d'une composition polymere a gelification rapide
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0317516D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
US7153870B2 (en) 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
US20050020587A1 (en) * 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
GB0317498D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Compounds
GB0317484D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
GB0317482D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
US7132435B2 (en) * 2003-07-25 2006-11-07 Pfizer Inc. Compounds
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
WO2005023253A1 (fr) * 2003-09-05 2005-03-17 Altana Pharma Ag Utilisation d'inhibiteurs de pde4 pour le traitement du diabete sucre
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
MXPA06007667A (es) * 2004-01-06 2006-09-01 Novo Nordisk As Heteroaril-ureas y su uso como activadores de glucocinasa.
WO2006073413A1 (fr) * 2004-02-20 2006-07-13 The Board Of Trustees Of The University Of Illinois Reduction de la pression sanguine dans l'hypertension dependant du sel
JP4793692B2 (ja) * 2004-04-26 2011-10-12 小野薬品工業株式会社 新規なｂｌｔ２介在性疾患、ｂｌｔ２結合剤および化合物
JP2008503446A (ja) * 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
MXPA06013305A (es) * 2004-05-17 2007-02-02 Otsuka Pharma Co Ltd Compuesto de tiazol y uso del mismo.
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
CA2583428A1 (fr) * 2004-09-03 2006-03-09 Plexxikon, Inc. Inhibiteurs de la phosphodiesterase 4b (pde4b)
US7704522B2 (en) * 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
EP1874308A1 (fr) 2005-03-08 2008-01-09 Nycomed GmbH Roflumilast pour le traitement de diabetes mellitus
WO2006094942A1 (fr) * 2005-03-08 2006-09-14 Nycomed Gmbh Roflumilast pour le traitement du diabète sucré
KR101358479B1 (ko) * 2005-04-19 2014-02-06 다케다 게엠베하 폐고혈압 치료용 로플루밀라스트
EP1904438B1 (fr) * 2005-07-08 2012-02-29 Novo Nordisk A/S Dicycloalkylcarbamoylurées en tant qu' activateurs de glucokinase
CN101263131B (zh) 2005-07-14 2013-04-24 特兰斯特克药品公司 脲葡糖激酶活化剂
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
EP2275096A3 (fr) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
CN1954882A (zh) * 2005-10-14 2007-05-02 李海 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
TWI435729B (zh) 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法，組合物及套組
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
JP5259592B2 (ja) * 2006-08-11 2013-08-07 メルク カナダ インコーポレイテッド Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008084043A1 (fr) * 2007-01-09 2008-07-17 Novo Nordisk A/S Activateurs de la glucokinase à base d'urée
JP5226008B2 (ja) 2007-01-11 2013-07-03 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
WO2009067618A1 (fr) * 2007-11-21 2009-05-28 Decode Genetics Ehf Inhibiteurs de benzoazole pde4 substitués pour le traitement de troubles pulmonaires et cardiovasculaires
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
CN102083801A (zh) * 2008-03-28 2011-06-01 康瑟特制药公司 喹唑啉衍生物和治疗方法
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
US8343912B2 (en) 2008-12-23 2013-01-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PL2443089T3 (pl) * 2009-06-18 2014-09-30 Concert Pharmaceuticals Inc Deuterowane pochodne izoindolino-1,3-dionu jako inhibitory pde4 i tnf-alfa
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2013106547A1 (fr) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
TWI617553B (zh) * 2013-03-13 2018-03-11 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
LT3009426T (lt) 2013-06-12 2018-07-25 Kaken Pharmaceutical Co., Ltd. 4-alkinilimidazolo darinys ir jį, kaip veiklųjį ingredientą, apimantis vaistas
TW201625591A (zh) * 2014-09-12 2016-07-16 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
CN108794620A (zh) * 2017-05-04 2018-11-13 南开大学 茶碱的偶联物及其制备方法与应用
EP3787637A4 (fr) 2018-02-07 2021-12-08 Duke University Système et procédé de phosphorylation du gpcr homogène et d'identification de modulateurs allostériques positifs des récepteurs bêta-2 adrénergique
MX2020008905A (es) 2018-06-12 2020-12-03 Vtv Therapeutics Llc Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
WO2025063819A1 (fr) * 2023-09-21 2025-03-27 오토텔릭바이오 주식회사 Composition pour le traitement d'une maladie fibrotique comprenant un composé dérivé de thiazole

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2140772A5 (en) 1971-06-07 1973-01-19 Aries Robert Phenoxynicotinoylaminophenols - analgesics tranquillisers antipyretics, anti-inflammatories and antirheumatics
US4270946A (en) * 1979-10-01 1981-06-02 Stauffer Chemical Company N-Aryl,2-phenoxy nicotinamide compounds and the herbicidal use thereof
US4692185A (en) * 1986-01-13 1987-09-08 Stauffer Chemical Company N-(ortho-substituted) benzyl, 3-trifluoromethylphenoxy nicotinamides as herbicides
US4861891A (en) 1988-08-31 1989-08-29 Pfizer Inc. Antidepressant N-substituted nicotinamide compounds
ATE174343T1 (de) 1991-02-27 1998-12-15 Lacer Sa Antihypertensive n-(alpha-substituiertes pyridyl)-carbonyldipeptide
DE4200323A1 (de) 1992-01-09 1993-07-15 Bayer Ag Herbizide und pflanzennematizide mittel auf basis von mercaptonicotinsaeurederivaten
HU225869B1 (en) 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
JPH08511805A (ja) 1993-06-18 1996-12-10 スミスクライン・ビーチャム・コーポレイション 化合物
JP3406689B2 (ja) 1994-03-15 2003-05-12 株式会社大塚製薬工場 ナフチリジン及びピリドピラジン誘導体
US5618027A (en) * 1994-07-20 1997-04-08 Nevrekar; Venkatesh R. Gate valve
EP0796096A4 (fr) 1994-12-23 1998-04-29 Smithkline Beecham Corp Monomeres 4,4-(disubstitues)cyclohexan-1-carboxylate et composes correspondants
TW429148B (en) * 1995-10-27 2001-04-11 Pfizer Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
US5922557A (en) 1997-01-09 1999-07-13 Merck & Co., Inc. System for stably expressing a high-affinity camp phosphodiesterase and use thereof
CN1254335A (zh) 1997-04-04 2000-05-24 辉瑞产品公司 烟酰胺衍生物
GB9715584D0 (en) * 1997-07-23 1997-10-01 Eisai Co Ltd Compounds
UA67753C2 (uk) 1997-10-10 2004-07-15 Смітклайн Бічам Корпорейшн Спосіб отримання заміщених 4-феніл-4-ціанциклогексанових кислот
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
MA24682A1 (fr) 1997-10-23 1999-07-01 Smithkline Beecham Corp Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant
AP2002002589A0 (en) * 2000-01-31 2002-09-30 Pfizer Prod Inc Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes.
HUP0204271A3 (en) * 2000-01-31 2003-07-28 Pfizer Prod Inc Pyrimidine carboxamides useful as inhibitors of pde4 isozymes, pharmaceutical compositions containing them and their use

Also Published As

Publication number Publication date
OA12542A (en) 2006-06-05
CZ20031903A3 (cs) 2004-07-14
JP2004518691A (ja) 2004-06-24
PL365443A1 (en) 2005-01-10
TNSN03050A1 (fr) 2005-12-23
WO2002060898A1 (fr) 2002-08-08
US20030130254A1 (en) 2003-07-10
CN1489588A (zh) 2004-04-14
IS6844A (is) 2003-06-16
EE200300362A (et) 2003-12-15
NO20033398L (no) 2003-09-29
US20020123520A1 (en) 2002-09-05
BG108039A (en) 2004-07-30
CA2436551A1 (fr) 2002-08-08
BR0116850A (pt) 2004-02-25
EP1355907A1 (fr) 2003-10-29
ZA200305769B (en) 2004-10-25
US6869945B2 (en) 2005-03-22
US20030186974A1 (en) 2003-10-02
NO20033398D0 (no) 2003-07-30
CR7038A (es) 2004-04-22
IL156412A0 (en) 2004-01-04
KR20030072614A (ko) 2003-09-15
AU2002222429A2 (fr) 2002-08-12
US6894041B2 (en) 2005-05-17
HUP0401305A2 (hu) 2004-10-28
MXPA03006886A (es) 2003-11-13
EA200300622A1 (ru) 2003-12-25
ECSP034683A (es) 2003-08-29
US6559168B2 (en) 2003-05-06

Similar Documents

Publication Publication Date Title
MA26985A1 (fr) Derives d'amides de thiazolyl-,oxazolyl-pyrrolyl-et imidazolyl-acides utiles comme inhibiteurs d'isozymes pde4
MA26983A1 (fr) Derives biaryliques de nicotinamide utiles comme inhibiteurs d'iso-enzymes pde4
MA26984A1 (fr) Derives d'ethers utiles comme inhibiteurs d'isozymes pde4
AU684887B2 (en) Isoxazoline compounds as inhibitors of TNF release
ES2262137T3 (es) Derivados de pirimidinamina farmacologicamente activos y procedimientos para su preparacion.
EP2297120B1 (fr) Dérivés d aminodihydrothiazine en tant qu inhibiteurs de bace destinés au traitement de la maladie d alzheimer
US9302984B2 (en) Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
AU2019250163A1 (en) Compositions and methods of modulating 15-PGDH activity
MA31865B1 (fr) Dérivés isoxazolo-pyridine
US20100137311A1 (en) Substituted pyrimidine derivatives
US20090170887A1 (en) Novel indazole derivative having spiro ring structure in side chain
US20160137630A1 (en) Induction of gata2 by hdac1 and hdac2 inhibitors
US5326770A (en) Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
JP7085686B2 (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾール誘導体化合物およびそれを含む薬剤学的組成物
MA26870A1 (fr) Derives heterocycliques benzocondenses de nicotinamide utiles comme inhibiteurs selectifs des isozymes pde4
RU2269519C2 (ru) Соединения фенилпиридазина и содержащие их лекарственные средства
KR20100075436A (ko) 칼륨 채널 조절제로서의 5-아미노-4,6-이치환된 인돌 및 5-아미노-4,6-이치환된 인돌린의 유도체
SK69794A3 (en) Pyridazines as inhibitors of enzyme, converting the interleukin-1-beta
MX9707652A (es) Derivados de 1,3-dihidro-1-(fenilalquil)-2h-imidazol-2-ona y composiciones que los contienen usados com inhibidores de fosfodiesterasa iv y de citocina, y procedimiento para preparar dichos derivados.
JP2021531335A (ja) ヒストンデアセチラーゼの二環式阻害剤
EA009372B1 (ru) N-ациламинобензольные производные в качестве селективных ингибиторов моноаминооксидазы в
JPH06199786A (ja) ジアミドフタリミドの置換誘導体
RU2248971C2 (ru) Производные пиримидин-2,4,6-трионов и фармацевтическая композиция, содержащая эти соединения
AU2006322461A1 (en) Pyrimidine derivatives and their use as KCNQ potassium channels openers
JP2001501221A (ja) Ｎｍｄａ（ｎ―メチル―ｄ―アスパラギン酸）アンタゴニスト